SGLT2-Inhibitoren für Herz und Niere

Was ist neu?

Funktion von SGLT2-Inhibitoren und pathophysiologische Effekte Natrium-Glukose-Co-Transporter-2-Inhibitoren (SGLT2) können die Glukose-Reabsorption im proximalen Tubulus blockieren und spielen damit eine wichtige Rolle in der Zuckerkontrolle beim Diabetes mellitus.

Erweiterung des Einsatzgebietes von SGLT2 Zusätzlich zur glukosurischen Wirkung wurden eher überraschend sehr umfangreiche, weitere positive Effekte bei chronischen Nierenfunktionsstörungen beobachtet. Auch zeigte sich eine starke kardioprotektive Wirkung bei der Herzinsuffizienz. Mittlerweile wurden zahlreiche Mechanismen abseits der reinen zuckerbeeinflussenden Wirkung der SGLT2-Inhibitioren identifiziert, die sowohl das Herz als auch die Niere direkt positiv beeinflussen können.

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors can block glucose reabsorption in the proximal tubule and thus play an important role in glycemic control in diabetes mellitus. In addition to glucosuric effects, surprisingly very extensive other positive effects were observed in chronic renal dysfunction and strong cardioprotective effects in heart failure. In the meantime, numerous mechanisms have been identified apart from the pure sugar-influencing effect of the SGLT2 inhibitors, which can have a direct positive influence heart and kidneys.

In recent years there has been an extensive clinical study program, which has dealt with the effects of SGLT2 inhibitors on the progression of diabetic and non-diabetic chronic renal failure. It could be shown that patients with albuminuria have a significant benefit from the use of SGLT2 inhibitors. Therefore, the progression of renal dysfunction is slowed down significantly, while at the same time, positive cardiovascular endpoints could be influenced. Numerous studies have also been conducted in patients with and without diabetes or with heart failure, with and without, preserved ejection fraction. Impressive protection was also shown here, with the benefit of using SGLT2 inhibitors to reduce heart failure worsening.

In a short period of 10 years, the use of SGLT2 inhibitors was established as an essential therapy for cardio-renal indications to inhibit the progression of renal failure as well as to protect against heart failure apart from pure diabetes therapy. In numerous guidelines (ESC heart failure, KDGIO diabetes, ESH hypertension), the early use of SGLT2 inhibitors is now recommended for protection against cardio-renal events and is an important first-line addition to the previously established therapies. Apart from diabetes therapy, it offers patients completely new options in cardio-renal protection.

Schlüsselwörter

Progression Niereninsuffizienz - kardio-renale Proektion - SGLT2-Inhibitor - Herzinsuffizienz - Diabetes

Keywords

Progression renal failure - cardio-renal progression - SGLT2 inhibitor - heart failure - diabetes

Publikationsverlauf

Artikel online veröffentlicht:
02. November 2023

• Literatur

• 1 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42 (36) 3599-3726 DOI: 10.1093/eurheartj/ehab368. (PMID: 34447992)
• 2 Kidney Disease. Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102 (Suppl. 05) S1-S127 DOI: 10.1016/j.kint.2022.06.008. (PMID: 36272764)
• 3 Mancia Chairperson G, Kreutz Co-Chair R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; DOI: 10.1097/HJH.0000000000003480..
• 4 Salvatore T, Carbonara O, Cozzolino D. et al. Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 2011; 12 (07) 658-666
• 5 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (04) 347-357 DOI: 10.1056/NEJMoa1812389. (PMID: 30415602)
• 6 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373 (22) 2117-2128 DOI: 10.1056/NEJMoa1504720. (PMID: 26378978)
• 7 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377 (07) 644-657 DOI: 10.1056/NEJMoa1611925. (PMID: 28605608)
• 8 Cherney DZI, Charbonnel B, Cosentino F. et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 2021; 64 (06) 1256-1267
• 9 Salvatore T, Galiero R, Caturano A. et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci 2022; 23 (07) 3651 DOI: 10.3390/ijms23073651. (PMID: 35409011)
• 10 Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400: 1788-1801 DOI: 10.1056/NEJMoa2204233. (PMID: 36331190)
• 11 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375 (04) 323-334 DOI: 10.1056/NEJMoa1515920. (PMID: 27299675)
• 12 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380 (24) 2295-2306 DOI: 10.1056/NEJMoa1811744. (PMID: 30990260)
• 13 Bhatt DL, Szarek M, Pitt B. et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2021; 384 (02) 129-139 DOI: 10.1056/NEJMoa2030186. (PMID: 33200891)
• 14 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383 (15) 1436-1446
• 15 Herrington WG, Staplin N, Wanner C. The EMPA-KIDNEY Collaborative Group. et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388 (02) 117-127
• 16 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381 (21) 1995-2008 DOI: 10.1056/NEJMoa1911303. (PMID: 31535829)
• 17 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383 (15) 1413-1424
• 18 Butler J, Packer M, Siddiqi TJ. et al. Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. J Am Coll Cardiol 2023; 81 (19) 1902-1914
• 19 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385 (16) 1451-1461
• 20 Solomon SD, McMurray JJV, Claggett B. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387 (12) 1089-1098 DOI: 10.1056/NEJMoa2206286. (PMID: 36027570)
• 21 Bhatt DL, Szarek M, Steg PG. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021; 384 (02) 117-128 DOI: 10.1056/NEJMoa2030183. (PMID: 33200892)